Level Four Advisory Services’s Madrigal Pharmaceuticals MDGL Stock Holding History

Level Four Advisory Services’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,140	Closed	-$911K	–	795
2022 Q4	$911K	Buy	+3,140	New	+$307K	0.07%	267

Other funds holding MDGL

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Level Four Advisory Services's MDGL Position: Q1 2023 in Review

Level Four Advisory Services sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2023, closing a stake of 3,140 shares — an estimated $911K sold.

Level Four Advisory Services first reported a position in MDGL in Q4 2022 and held it in 1 quarter. The position peaked at $911K in Q4 2022. 223 funds tracked by Wall St. Rank hold MDGL as of Q1 2023.

Level Four Advisory Services reported no remaining Madrigal Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Level Four Advisory Services sold 3,140 Madrigal Pharmaceuticals shares in Q1 2023, an estimated $911K.
Level Four Advisory Services first reported a position in Madrigal Pharmaceuticals in Q4 2022 and held it in 1 quarter.
Level Four Advisory Services's Madrigal Pharmaceuticals position peaked at $911K in Q4 2022.
223 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2023.

Based on Level Four Advisory Services's 13F filing for Q1 2023, filed 5 Jun 2023.